$2.11
-0.15-6.64%
At close: -
$2.11
0.000.00%
After Hours: Apr 25, 4:00 PM EDT
Comments
Loading...
Inhibikase Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:IKT | Benzinga
Inhibikase Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
May 9
EPS Estimate
$-0.100
Quarterly Revenue Estimate
–
Annual Revenue
(as of Dec 31)
(as of Dec 31)
–
Analyze the earnings history of Inhibikase Therapeutics using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IKT | Inhibikase Therapeutics | -$0.73 | -$0.11 | — | — | $0.00 | — | — | — | 05/14/2025 | Get Alert |
| IKT | Inhibikase Therapeutics | -$0.64 | -$0.10 | — | — | $1.00K | — | — | — | 05/09/2025 | Get Alert |
| IKT | Inhibikase Therapeutics | -$0.75 | -$0.67 | -$0.65 | 2.99% | $79.57K | — | $0.00 | — | 11/14/2024 | Get Alert |
| IKT | Inhibikase Therapeutics | -$0.94 | -$0.67 | -$0.66 | 1.49% | $116.41K | — | $0.00 | — | 08/14/2024 | Get Alert |
| IKT | Inhibikase Therapeutics | -$0.96 | -$0.79 | -$0.73 | 7.59% | $64.52K | — | $0.00 | — | 05/15/2024 | Get Alert |
| IKT | Inhibikase Therapeutics | -$1.02 | -$0.85 | -$0.64 | 24.71% | $63.57K | — | $1.00K | — | 03/27/2024 | Get Alert |
| IKT | Inhibikase Therapeutics | -$1.08 | -$1.19 | -$0.86 | 27.73% | $7.29K | — | $79.57K | — | 11/14/2023 | Get Alert |
| IKT | Inhibikase Therapeutics | -$1.08 | -$0.92 | -$1.11 | -20.65% | $6.55K | — | $116.41K | — | 08/14/2023 | Get Alert |
| IKT | Inhibikase Therapeutics | -$1.08 | -$0.84 | -$0.96 | -14.29% | $46.03K | — | $64.52K | — | 05/15/2023 | Get Alert |
| IKT | Inhibikase Therapeutics | -$1.20 | -$1.14 | -$1.02 | 10.53% | $1.94M | — | $63.57K | — | 03/31/2023 | Get Alert |
| IKT | Inhibikase Therapeutics | -$1.08 | -$1.08 | -$1.08 | 0.00% | $328.46K | $200.00K | $7.29K | -96.35% | 11/14/2022 | Get Alert |
| IKT | Inhibikase Therapeutics | -$1.32 | -$1.14 | -$1.08 | 5.26% | $1.36M | $300.00K | $6.55K | -97.82% | 08/12/2022 | Get Alert |
| IKT | Inhibikase Therapeutics | -$1.56 | -$1.02 | -$1.08 | -5.88% | $1.41M | $300.00K | $46.03K | -84.66% | 05/16/2022 | Get Alert |
| IKT | Inhibikase Therapeutics | -$0.90 | -$1.02 | -$1.20 | -17.65% | $170.42K | $300.00K | $1.94M | 548.00% | 03/31/2022 | Get Alert |
| IKT | Inhibikase Therapeutics | -$0.48 | -$0.84 | -$1.08 | -28.57% | $37.68K | $328.00K | $328.46K | 0.14% | 11/15/2021 | Get Alert |
| IKT | Inhibikase Therapeutics | -$0.30 | -$2.28 | -$1.32 | 42.11% | $219.59K | $300.00K | $1.36M | 354.33% | 08/16/2021 | Get Alert |
| IKT | Inhibikase Therapeutics | -$0.42 | — | -$1.56 | — | — | — | $1.41M | — | 05/17/2021 | Get Alert |
| IKT | Inhibikase Therapeutics | -$0.30 | — | -$0.90 | — | — | — | $170.42K | — | 04/01/2021 | Get Alert |
Inhibikase Therapeutics (IKT) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | 2024-11-14 | $-0.65 | $-0.67 | 2.99 % |
| Q2 | 2024-08-14 | $-0.66 | $-0.67 | 1.49 % |
| Q1 | 2024-05-15 | $-0.73 | $-0.79 | 7.59 % |
| Q4 | 2024-03-27 | $-0.64 | $-0.85 | 24.7 % |
Inhibikase Therapeutics (IKT) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | 2022-11-14 | $7.29K | $200.00K | -96.4 % |
| Q2 | 2022-08-12 | $6.55K | $300.00K | -97.8 % |
| Q1 | 2022-05-16 | $46.03K | $300.00K | -84.7 % |
| Q4 | 2022-03-31 | $1.94M | $300.00K | 548.0 % |
FAQ
When is Inhibikase Therapeutics (NASDAQ:IKT) reporting earnings?
Inhibikase Therapeutics (IKT) is scheduled to report earnings on May 14, 2025. The last reported earnings were for reported on November 14, 2024 for Q3.
What were the latest earnings per share (EPS) for Inhibikase Therapeutics (NASDAQ:IKT)?
The Actual EPS was $-0.65, which beat the estimate of $-0.67.
What were Inhibikase Therapeutics’s (NASDAQ:IKT) revenues?
The Actual Revenue was $0K, which hit the estimate of $0K.
Browse earnings estimates, EPS, and revenue on all stocks.
